2020
CRL4 Ubiquitin Pathway and DNA Damage Response. Adv Exp Med Biol. 2020;1217:225-239.
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 2020;60:102988.
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4(20):5226-5231.
Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2020;61(12):2894-2899.
DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. Nat Microbiol. 2020;5(8):1051-1063.
The strengths and weaknesses of viscoelastic testing compared to traditional coagulation testing. Transfusion. 2020;60 Suppl 6:S21-S28.
Functional annotation of human long noncoding RNAs via molecular phenotyping. Genome Res. 2020;30(7):1060-1072.
The use of coagulation factor concentrates for perioperative bleeding management - a global perspective. Transfusion. 2020;60(4):663-666.
Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2020;585(7826):E20.